Association of vitiligo with immune-checkpoint inhibitor therapy: A systematic review

JAAD Int. 2024 Nov 14:18:119-121. doi: 10.1016/j.jdin.2024.10.005. eCollection 2025 Feb.

¹ School of Medicine, New York Medical College, Valhalla, New York.
² Department of Dermatology, Georgetown University School of Medicine, Medstar Washington Hospital Center, Washington, District of Columbia.
³ Department of Dermatology, Weill Cornell Medicine, New York, New York.

No abstract available

Keywords: immune-related adverse events; immunotherapy; immunotoxicity; nivolumab; pembrolizumab; vitiligo.